老虎证券

美股详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Innate Pharma SA

2.04
+0.04502.26%
成交量：1.87万
成交额：3.74万
市值：1.71亿
市盈率：-4.51
高：2.05
开：1.99
低：1.96
收：2.00
数据加载中...
总览公司新闻公告
2024/09/11

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/04/04

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/01/12

SEC问询函

Form CORRESP - Correspondence
2023/04/20

[修订]年度报告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/06

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/12/06

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/10/21

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/04/04

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/07/12

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/05/11

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/04/27

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/03/16

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2021/02/12

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/01/27

SEC问询函

CORRESP [Cover] - Correspondence
2020/04/24

年度报告

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/14

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
更多